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Background and Objectives: This study was to evaluate whether high body mass index (BMI) or thyroid 
stimulating hormone (TSH) level would affect selecting thyroid nodule for fine-needle aspiration biopsy (FNA) 
after ultrasound (US) evaluation. Materials and Methods: A total of 3155 thyroid nodules (2159 benign and 996 
malignant nodules) were included. Four grades of BMI and three levels of TSH were applied for grouping. US 
features of the thyroid nodules were divided into ‘probably benign’ and ‘suspicious for malignancy’ categories. 
Patients were grouped according to gender and univariate and multivariate logistic regression analysis were 
used to find the association between variables and malignancy. Results: TSH levels were significantly higher 
in the malignant group (p＜0.001). The grades of BMI did not show difference between the malignant and 
benign groups (females, p=0.074 and males, p=0.157). Younger age and ‘suspicious for malignancy’ US 
category were independent risk factors for malignancy in both genders. In females, a high TSH level (odds 
ratio=1.010, p＜0.001) had significant association with malignancy. Except for younger age (odds ratio=0.998, 
p＜0.001), no variable in nodules with ‘probably benign’ US category was significantly associated with 
malignancy. Conclusion: High TSH levels were more frequent in thyroid malignancy group, but neither high BMI 
nor high TSH level give additional information for FNA selection after US.
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Introduction
Thyroid cancer incidence has been sharply in-
creasing worldwide during the last few decades.1,2) 
This is partially due to increased medical surveillance 
and the widespread use of highly sensitive diagnostic 
tools such as ultrasound (US) and fine-needle aspira-
tion biopsy (FNA).1) However, the increased incidence 
of large papillary thyroid cancer cannot be explained 
solely by these reasons.3) 
There are many potential risk factors for thyroid 
cancer such as ionizing radiation, history of thyroid 
cancer in first degree relatives, prior history of thyroid 
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cancer, and a high calcitonin level.4,5) Recently, atten-
tion has been drawn toward obesity, which may be 
another potential risk factor for thyroid cancer, as there 
was a dramatic increase in the prevalence of both 
thyroid cancer and obesity during the similar period.3,6) 
Up to the present, the best level of evidence has been 
derived from a pooled analysis of prospective studies 
(n=848,932) showing that obesity is an independent 
risk factor for thyroid cancer (hazard ratio: 1.21 in 
men and 1.16 in women).7) This was also true in a 
health checkup setting with 15068 subjects and with 
FNA results of 1427 patients; the prevalence of thy-
roid cancer in women was associated with a high 
body mass index (BMI), per 5 kg/m2 increase (odds 
ratio [OR], 1.63; p＜0.001).8) Along with high BMI, a 
high thyroid stimulating hormone (TSH) level was re-
ported to be a risk factor for malignant thyroid 
nodules.9-11) There was a positive association between 
BMI and TSH levels in a study that included euthyroid 
patients12,13) as well as hypothyroidism patients.14) 
Although association between thyroid cancer and 
high BMI or high TSH level has been reported, risk 
stratification of thyroid nodules detected on US follows 
the US feature of nodules. Therefore, the most im-
portant factor that determines the need for FNA is US 
features of a thyroid nodule, not BMI or TSH level. 
None of the previous studies have evaluated the as-
sociation of high BMI or TSH levels with thyroid malig-
nancy after adjusting for US features and it remains 
unclear whether these two potential risk factors would 
affect nodule selection for FNA. Therefore, the purpose 
of this study was to evaluate whether high BMI or TSH 
levels would affect the selection of thyroid nodules for 
FNA after US evaluation, an essential procedure for 
choosing an adequate treatment plan.
Materials and Methods
This retrospective study was approved by the in-
stitutional review board, and informed consent was 
waived. Informed consent for US-guided FNA was 
obtained from all patients prior to each biopsy.
Study Population
Among thyroid nodules that were biopsied in our 
institution from February 2006 through December 
2008 (13,182 nodules in 12,028 patients), we se-
lected 3698 nodules with the following criteria; nod-
ules 5 mm or larger, nodules found in patients without 
thyroid hormone medication history, and those found 
in patients with information on height, weight, and TSH 
values available on medical records within three 
months from the day of FNA. Among the biopsied 
nodules, 3954 nodules were operated. Five hundred 
forty three nodules in 536 patients were excluded due 
to a lack of definitive cytologic or further pathologic di-
agnosis following surgery. In the study period, cyto-
logical reports were categorized as ‘benign’, 
‘indeterminate’, ‘suspicious for papillary thyroid carci-
noma’, ‘malignant’, or ‘nondiagnostic’.15-18) Definitive 
cytologic results for analysis included ‘benign’ and 
‘malignant’. We excluded 230 nodules (42.4%) with 
nondiagnostic, 95 (17.5%) nodules with indeterminate, 
and 218 (40.1%) nodules with suspicious for malig-
nancy cytologic results. Finally, 3155 nodules in 3005 
patients were included as the study population. 
Data Acquisition and Patient Grouping
Patients were grouped according to gender. Clinical 
information was systematically summarized and col-
lected from electronic medical records by a 4th year 
resident and a trained employee who had worked in 
our radiology department for 5 years. The patients in-
cluded in this study had records available of their 
height, weight, and serum TSH levels for each day of 
their outpatient clinic visits within three months from the 
day of FNA. The BMI was calculated (weight (kg)/ 
height (m2)) using each patient’s height and weight. 
Patients were assigned four grades according to BMI 
using the World Health Organization classification; un-
derweight with BMI ＜18.5; normal with BMI 18.5 to 
24.9; overweight with BMI 25 to 29.9, and obese with 
BMI ≥30.19) Our institution’s TSH assay method al-
tered from radioimmunoassay to IRMA method during 
the study period. Therefore, TSH levels were de-
termined by radioimmunoassay (Trinity Biotech, Co. 
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Wicklow, Ireland, reference range 0.4-3.1 μIU/mL) or 
IRMA (TSH-CTK-3, SORIN Biomedica, Saluggia, Italy, 
reference range 0.3-4.99 μIU/mL). The reference 
ranges of the two TSH level measurement methods 
were based on each company’s recommendation. 
TSH values were classified into three levels, low (lower 
than reference range), normal (within reference 
range), and high (higher than reference range).
Ultrasound Evaluation and FNA
Images of US were obtained using 5-12 MHz linear 
transducers (HDI 5000 and IU-22, respectively; 
Philips, Bothell, WA, USA). Ultrasonographic features of 
the thyroid nodules that underwent US-guided FNA 
were recorded according to internal component, 
echogenicity, margin, calcification, shape, and vascu-
larity (Appendix). Suspicious US features include 
marked hypoechogenicity, microlobulated or irregular 
margin, microcalcification, taller than wide shape. 
Nodules are considered ‘suspicious for malignancy’ if 
there is one or more of the above suspicious US 
features. Nodules with no suspicious US features are 
considered as ‘probably benign’. Based on US fea-
tures, thyroid nodules were divided into two catego-
ries, ‘probably benign’ and ‘suspicious for malig-
nancy’.20) 
All FNA on thyroid nodules was done under US 
guidance. For FNA, a 23-gauge needle attached to 
a 2-mL disposable plastic syringe was used. In each 
nodule, aspiration was done twice or more and aspi-
rated materials were expelled onto glass slides fol-
lowed by smearing. All smeared glass slides were 
placed in 95% alcohol for Papanicolaou staining and 
the remaining material was rinsed in saline solution. 
After the glass slides of expelled aspirated material 
were moved to the pathologic department, they were 
interpreted by five experienced cytopathologists. 
Statistical Analysis
Two sample t-tests were used to compare con-
tinuous variables including age, nodule size, height, 
and weight of patients in the malignant and benign 
nodule groups. The Chi-square test was used to 
compare categorical variables including BMI grade, 
TSH level, and US category in the two groups. 
The OR with 95% confidence intervals (CI) of malig-
nancy for each clinical and US feature was calculated 
with univariate and multivariate logistic regression 
analysis. As some previous studies showed a positive 
association between BMI and TSH levels, we analyzed 
their association.13,21) We evaluated the association 
between BMI and TSH levels (both in multimodal dis-
tribution) by using cumulative logit link and it was not 
significant (p=0.318). Therefore, we included both BMI 
value and TSH level as independent variables in mul-
tivariate logistic regression analysis. After adjusting for 
all factors in the univariate analysis except for height 
and weight, which were used to calculate BMI, multi-
variate logistic regression analysis was performed to 
assess independent associations of thyroid malig-
nancy with all clinical factors and US categories. To 
evaluate the effect of clinical factors on nodule se-
lection for FNA, univariate and multivariate logistic re-
gression analysis was done for nodules of each US 
category. We used logistic regression with GEE 
(generalized estimating equation) for clustered data. 
SAS ver. 9.2 (SAS Inc., Cary, NC, USA) was used for 
statistical analysis. A p value of less than 0.05 was 
considered significant for statistical analysis. 
Results
Among 3155 nodules, 2663 nodules were in fe-
male and 492 nodules were in male. Among the nod-
ules, there were 2159 benign and 996 malignant 
nodules. There were 2088 patients with benign nod-
ules; 2017 patients had one benign nodule and 71 
patients had two benign nodules. There were 933 
patients with malignant nodules; 870 patients had one 
malignant nodule and 63 patients had two malignant 
nodules. Sixteen patients had both malignant and be-
nign nodules; 15 patients had one malignant and one 
benign nodule and one patient had two malignant and 
one benign nodule. 
The number of nodules with each clinical and US 
feature is shown in Table 1. Patients with malignant 
nodules were significantly younger compared to pa-
tients with benign nodules in both genders (p＜0.001). 
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Malignant nodules had significantly smaller size in both 
genders (p＜0.001). In both genders, the grades of 
BMI showed no significant difference between the 
malignant and benign groups (female, p=0.074; male, 
p=0.157). TSH levels were significantly different be-
tween the malignant and benign groups in both gen-
ders (p＜0.001) showing a higher percentage of high 
TSH levels among the malignant group (12.6-23.9%) 
compared to the benign group (7.1-12.1%). The US 
‘suspicious for malignancy’ category was significantly 
more frequent in the malignant group compared to the 
benign group in both genders (p＜0.001). 
In both genders, younger age and ‘suspicious for 
malignancy’ US category was significantly associated 
with malignancy on multivariate logistic regression 
analysis (Table 2). In females, a high TSH level 
(OR=1.010, p＜0.001) and smaller nodule size 
(OR=0.999, p=0.044) also had significant association 
with malignancy on multivariate analysis. In males, low 
BMI (underweight; OR=1.145, p=0.025) was sig-
nificantly associated with malignant thyroid nodules on 
multivariate analysis. In both genders, a low TSH level 
was significantly associated with decreased risk of 
malignancy (OR=0.766-0.896, p＜0.001-0.012). 
The results of multivariate logistic regression analy-
sis for each US category are shown in Table 3. In 
‘probably benign’ US category, younger age was 
significantly associated with malignancy in both 
genders. In females, smaller nodule was significantly 
associated with malignancy in ‘probably benign’ US 
category. In nodules with ‘suspicious for malignancy’ 
US category, younger age was significantly associated 
with malignancy in both genders. 
Regarding BMI grade, it did not show any significant 
association with malignancy in females in both US 
categories. In males, low BMI was significantly asso-
ciated with malignancy among nodules with 
‘suspicious for malignancy’ US category. Regarding 
TSH levels, high TSH level was significantly associated 
with malignancy in females in ‘suspicious for malig-
nancy’ US category, but not in males. In both genders, 
low TSH level was significantly associated with de-
creased risk of malignancy in ‘suspicious for malig-
nancy’ US category. 
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Discussion
In this study, malignant thyroid nodules were sig-
nificantly associated with ‘suspicious for malignancy’ 
US category in both genders on multivariate analysis. 
In terms of TSH and BMI, there were different results 
according to the gender on multivariate analysis. High 
TSH levels in females and low BMI grades in males 
were significantly associated with malignancy. 
However, when we evaluated the association of thy-
roid malignancies according to US category, neither a 
BMI grade nor a TSH level was significantly associated 
with malignancy in nodules with the ‘probably benign’ 
US category. On the other hand, a high TSH level in 
females and a low BMI grade in males were sig-
nificantly associated with malignancy in nodules with 
the ‘suspicious for malignancy’ US category. 
Therefore, neither a BMI grade nor TSH levels have 
additional value in the selection of thyroid nodules for 
FNA after adequate categorization with US. These re-
sults are important because, to date, although the sig-
nificant associations between malignancy and BMI or 
TSH levels have been studied,7-10) there has been no 
study showing whether different approaches are 
needed for patients with BMI or TSH levels when per-
forming FNA. 
Before multivariate analysis was done to evaluate 
clinical factors and malignant thyroid nodules, we per-
formed the interaction test between BMI and TSH be-
cause a high BMI and TSH level have been shown to 
have positive association with thyroid malignancy.12,13,21) 
It is well known that TSH is related to the energy me-
tabolism of the body,22) and perhaps due to the higher 
prevalence of hypothyroidism in obesity, there are 
early studies showing increased TSH levels in patients 
with high BMI.14,23) However, in our study, there was 
no significant association between BMI values and 
TSH levels, i.e., increasing BMI values and high TSH 
levels did not show significant association. Therefore, 
it was possible to include both BMI grade and TSH 
level as confounding factors in multivariate analysis to 
evaluate their association with malignant thyroid 
nodules.
The association between high BMI, TSH level, and 
risk of thyroid cancer cannot be explained in a simple 
manner. One proposed mechanism is explained by the 
role of leptin, which is an adipokine and known to be 
related to obese patients.24) Elevated leptin levels will 
increase susceptibility to thyroid autoimmunity, which 
can lead to hypothyroidism and elevated TSH levels.25) 
Another main mechanism is explained by insulin re-
sistance in obese patients.26) Insulin resistance, which 
is also related to diabetes mellitus, increases the insulin 
level in obese patients. Insulin can promote the secre-
tion of regulatory factors including adipocytokines and 
TSH.26) In either of the suggested mechanisms, a high 
BMI will lead to a subsequent elevated TSH level and 
the increased amount of TSH stimulates the production 
of thyroid hormones and influences the growth and 
differentiation of thyroid cells.27) The positive association 
between a high TSH level and increased risk of thyroid 
cancer28) and its aggressiveness29) have been 
revealed. Recently, therapeutic strategy for thyroid 
cancer by means of controlling obesity with a drug has 
also been studied in mouse models.30) 
TSH stimulates the production of thyroid hormones 
and supports thyroid growth.27) Although it is still con-
troversial, some conclude that TSH receptor stim-
ulation is related to the increased incidence and ag-
gressiveness of thyroid cancer,29) and there are re-
ports that a high TSH level was significantly associated 
with thyroid malignancy.9,10) On the other hand, sup-
pression of TSH prevents the growth of thyroid 
nodules.31) In our study, although it was not a sig-
nificant factor in determining nodules for FNA, a high 
TSH level was significantly associated with malignancy 
in both univariate and multivariate analysis. 
In a previous study, a low TSH level was associated 
with a lower risk of thyroid malignancy.32) According 
to our results, low TSH levels were found to decrease 
risk of malignancy in both genders. There were 14.7% 
(318/2159) of benign nodules with suspicious US 
features in our study, therefore, if we can exclude 
those nodules for FNA, it will decrease the number of 
unnecessary FNAs. Further studies are needed to 
show the association between low TSH levels and 
lower risk of thyroid malignancy combined with US 
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features of thyroid nodules. 
Our results showing significant association between 
underweight (i.e., a low BMI grade) and thyroid malig-
nancy in males is novel and not yet recognized. Most 
of the studies showing association between low BMI 
and cancer regards low BMI factor as a poor prog-
nostic factor after surgery.33,34) Still, in contrast to high 
BMI and cancer, there is a lack of report showing pos-
itive association between low BMI and malignancy. 
However, a recent study with a large cohort showed 
underweight was significantly associated with in-
creased risk of breast cancer in premenopausal 
women.35) Since number of males with low BMI was 
limited in our study, the relationship between thyroid 
malignancy and low BMI in males warrants further 
confirmation. 
According to our results, smaller nodules were as-
sociated with malignancy in females. There are con-
tradictory results regarding the thyroid nodule size and 
the risk of malignancy. Some studies show consistent 
result with ours, showing inverse relationship between 
the thyroid nodule size and risk of malignancy.36,37) 
Still, other studies reported that a larger nodule is as-
sociated with higher risk of malignancy.38,39) The high-
er malignancy rate in smaller nodules in our study 
could be related to higher rate of FNA on smaller 
nodules with suspicious US feature. There were some 
limitations to our study. First, there is an inevitable se-
lection bias in our study. If a patient did not undergo 
surgery after FNA with inconclusive cytological results 
(indeterminate, suspicious for papillary thyroid carci-
noma, or nondiagnostic), those nodules were ex-
cluded from the study subjects. Second, there is a 
possibility of false-negative or false-positive results for 
the thyroid nodules, as we included FNA cytological 
results, not surgical pathology, of malignant and be-
nign nodules. However, we cannot attribute the po-
tential misinterpretation of the results to false results on 
FNA, as previous studies conducted in our institution 
showed a relatively low rate of false-negative 
(1.9-3.2%) or false-positive (1.9%) results.16,40) Third, 
there was a relatively small number of obese patients 
(3.23%, n=102) in our study population, which may 
limit the hazard assessment of the various factors. 
Different results may be found in other study pop-
ulations with a higher proportion of obese patients 
such as in western countries. Lastly, there were two 
different methods for TSH assay and associated two 
different reference levels for normal TSH level. 
According to a previous study, although the two assay 
methods well correlate with each other, IRMA was 
more sensitive than radioimmunoassay.41) 
In conclusion, although there were more malignant 
thyroid nodules in patients with a high BMI grade or 
high TSH level, high BMI and high TSH levels were 
not significant factors in the determination of thyroid 
nodules for FNA when considered with US features.
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Appendix. Ultrasonographic features of the thyroid nodules 
In our institution, the echogenicity of thyroid nodules was classified as followings; hyperechogenic 
(hyperechogenic compared to the normal thyroid gland), isoechogenic (isoechogenic compared to the normal 
thyroid gland), hypoechogenic (hypoechogenic compared to the normal thyroid gland but hyperechogenic to the 
surrounding strap muscle), and marked hypoechogenic (hypoechogenic compared to the surrounding strap mus-
cle). Nodule margins are classified as well-circumscribed, microlobulated, and irregular. Calcifications are classified 
as microcalcification (calcification less than 1 mm), macrocalcification (calcification 1 mm or larger), eggshell calcifi-
cation, and no calcification. Nodule shape is classified as wider than tall (transverse diameter to the anteroposterior 
diameter ratio ＜1) and taller than wide (transverse diameter to the anteroposterior diameter ratio ≥1).20) 
